...
首页> 外文期刊>Journal of proteomics >Quantitative clinical proteomic study of autopsied human infarcted brain specimens to elucidate the deregulated pathways in ischemic stroke pathology
【24h】

Quantitative clinical proteomic study of autopsied human infarcted brain specimens to elucidate the deregulated pathways in ischemic stroke pathology

机译:尸体解剖的人体梗死脑标本的定量临床蛋白质组学研究,以阐明缺血性中风病理学中失控的途径

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Ischemic stroke, still lacking an effective neuroprotective therapy is the third leading cause of global mortality and morbidity. Here, we have applied an 8-plex iTRAQ-based 2D-LC-MS/MS strategy to study the commonly regulated infarct proteome from three different brain regions (putamen, thalamus and the parietal lobe) of female Japanese patients. Infarcts were compared with age-, post-mortem interval- and location-matched control specimens.The iTRAQ experiment confidently identified 1520 proteins with 0.1% false discovery rate. Bioinformatics data mining and immunochemical validation of pivotal perturbed proteins revealed a global failure of the cellular energy metabolism in the infarcted tissues as seen by the parallel down-regulation of proteins related to glycolysis, pyruvate dehydrogenase complex, TCA cycle and oxidative phosphorylation. The concomitant down-regulation of all participating proteins (SLC25A11, SLC25A12, GOT2 and MDH2) of malate-aspartate shuttle might be responsible for the metabolic in-coordination between the cytosol and mitochondria resulting in the failure of energy metabolism. The levels of proteins related to reactive gliosis (VIM, GFAP) and anti-inflammatory response (ANXA1, ANXA2) showed an increasing trend. The elevation of ferritin (FTL, FTH1) may indicate an iron-mediated oxidative imbalance aggravating the mitochondrial failure and neurotoxicity. The deregulated proteins could be useful as potential therapeutic targets or biomarkers for ischemic stroke. Biological significance: Clinical proteomics of stroke has been lagging behind other areas of clinical proteomics like Alzheimer's disease or schizophrenia. Our study is the first quantitative clinical proteomics study where iTRAQ-2D-LC-MS/MS has been utilized in the area of ischemic stroke to obtain a comparative profile of human ischemic infarcts and age-, sex-, location- and post-mortem interval-matched control brain specimens. Different pathological attributes of ischemic stroke well-known through basic and pre-clinical research such as failure of cellular energy metabolism, reactive gliosis, activation of anti-inflammatory response and aberrant iron metabolism have been observed at the bedside. Our dataset could act as a reference for similar studies done in the future using ischemic brain samples from various brain banks across the world. A meta-analysis of these studies could help to map the pathological proteome specific to ischemic stroke that will guide the scientific community to better evaluate the pros and cons of the pre-clinical models for efficacy and mechanistic studies.Infarct being the core of injury should have the most intense regulation for several key proteins involved in the pathophysiology of ischemic stroke. Hence, a part of the up-regulated proteome could leak into the general circulation that may offer candidates of interest as potential biomarkers. In support of our proposed hypothesis, we report ferritin in the current study as one of the most elevated proteins in the infarct, which has been documented as a biomarker in the context of ischemic stroke by an independent study. Overall, our approach has the potential to identify probable therapeutic targets and biomarkers in the area of ischemic stroke.
机译:仍然缺乏有效的神经保护疗法的缺血性中风是全球死亡率和发病率的第三个主要原因。在这里,我们应用了一种基于8重iTRAQ的2D-LC-MS / MS策略,研究了日本女性患者三个不同大脑区域(丘脑,丘脑和顶叶)的常见调节梗死蛋白。将梗塞与年龄,验尸间隔和位置匹配的对照标本进行比较。iTRAQ实验自信地鉴定出1520种蛋白质,错误发现率为0.1%。生物信息学数据挖掘和关键扰动蛋白的免疫化学验证显示,与糖酵解,丙酮酸脱氢酶复合物,TCA循环和氧化磷酸化相关的蛋白平行下调可以看出,梗塞组织中细胞能量代谢的整体失败。苹果酸-天冬氨酸穿梭蛋白的所有参与蛋白(SLC25A11,SLC25A12,GOT2和MDH2)的伴随下调可能是造成细胞质与线粒体之间代谢不协调的原因,导致能量代谢失败。与反应性神经胶质增生(VIM,GFAP)和抗炎反应(ANXA1,ANXA2)相关的蛋白质水平呈上升趋势。铁蛋白(FTL,FTH1)的升高可能表明铁介导的氧化失衡加剧了线粒体衰竭和神经毒性。失调的蛋白质可用作缺血性中风的潜在治疗靶标或生物标志物。生物学意义:中风的临床蛋白质组学一直落后于其他临床蛋白质组学领域,例如阿尔茨海默氏病或​​精神分裂症。我们的研究是第一个定量临床蛋白质组学研究,其中iTRAQ-2D-LC-MS / MS在缺血性卒中领域得到了利用,从而获得了人类缺血性梗死以及年龄,性别,位置和死后状况的比较资料间隔匹配的对照脑标本。通过基础和临床前研究众所周知的缺血性中风的不同病理属性,例如细胞能量代谢失败,反应性神经胶质增生,抗炎反应的激活和铁代谢异常,都在床边被观察到。我们的数据集可以用作将来使用来自世界各地不同大脑库的缺血性脑样本进行的类似研究的参考。对这些研究的荟萃分析可以帮助绘制缺血性中风特有的病理蛋白质组图,这将指导科学界更好地评估临床前模型的有效性和机理研究的利弊。梗塞应作为损伤的核心对缺血性中风的病理生理过程中涉及的几种关键蛋白有最严格的调节作用。因此,部分上调的蛋白质组可能会渗入一般循环中,从而可能提供感兴趣的候选物作为潜在的生物标志物。为了支持我们提出的假设,我们在当前研究中将铁蛋白报告为梗死灶中蛋白水平最高的蛋白之一,独立研究已将其作为缺血性卒中的生物标志物进行了记录。总体而言,我们的方法具有识别缺血性卒中领域中可能的治疗靶标和生物标志物的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号